NCT04899921View on ClinicalTrials.gov

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

May 29, 2023

Study Completion Date

May 29, 2023

Conditions
MelanomaMetastatic Melanoma
Interventions
DRUG

Ipilimumab

Intravenous injection

DRUG

Nivolumab

Intravenously (IV) into the vein

DRUG

Troriluzole

Taken orally

DRUG

Placebo

Taken orally

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Biohaven Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER